Our study found that 10 (9%) COVID-19 patients were EBV-VCA IgM and CMV IgM seropositive, 5 (4.5%) COVID-19 patients were EBV-VCA IgM seropositive, and 5 (4.5%) COVID-19 patients were CMV IgM seropositive. This evidence concerns the gene CD40LG and COVID-19.